The focus clearly has shifted to Tx. Almost as if the Dx is a done deal.

Here's the only mention.

Quote:

---

Amarantus BioScience Holdings (AMBS)

Amarantus is a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications. The Company has already received Orphan Drug Designation from the FDA for the treatment of Retinitis Pigmentosa.

Amarantus’ lead therapeutic program, eltoprazine is a small molecule indicated for the treatment of Levodopa-induced dyskinesia and is expected to enter a Phase 2b clinical trial in the second quarter of 2015. Eltoprazine is also being evaluated for the treatment of adult attention deficit hyperactivity disorder (ADHD) and Alzheimer’s aggression. Amarantus is developing MANF (mesencephalic-astrocyte-derived neurotrophic factor), for the treatment of brain and ophthalmic disorders.

For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

---

http://philasecurities.com/events/ambs/